Table 1 Baseline demographic and clinical characteristics of study patients
Parameter | Drug group (Frankincense) (n = 33) | Control group (n = 37) | P-value |
|---|---|---|---|
Age (years; mean ± SD) | 59.82 ± 9.00 | 57.32 ± 8.18 | 0.229 |
Sex (n) | |||
Male | 4 (12.1%) | 4 (10.8%) | 1.000 |
Female | 29 (87.9%) | 33 (89.2%) | |
Duration of OA (month; mean [IQR]) | 54 [30–87] | 36 [12–87] | 0.158 |
Comorbidity (n) | |||
Diabetes | 1 (3.0%) | 1 (2.7%) | |
Hypertension | 2 (6.1%) | 4 (10.8%) | |
Dyslipidemia | 3 (9.1%) | 1 (2.7%) | |
Hypothyroidism | 0 (0.00%) | 3 (8.1%) | |
Hyperthyroidism | 1 (3.0%) | 0 (0.00%) | |
Migraine | 2 (6.1%) | 1 (2.7%) | |
Hypertension + Dyslipidemia | 2 (6.1%) | 2 (5.4%) | |
Diabetes + Dyslipidemia | 1 (3.0%) | 1 (2.7%) | |
Hypothyroidism + Hypertension | 1 (3.0%) | 0 (0.00%) | |
Hypothyroidism + Diabetes | 0 (0.00%) | 1 (2.7%) | |
Hypothyroidism + Diabetes + Dyslipidemia | 0 (0.00%) | 2 (5.4%) | 0.469 |
Hypothyroidism + Diabetes + Dyslipidemia + Hypertension | 0 (0.00%) | 1 (2.7%) | |
Concurrent drugs (n) | |||
Metformin | 0 (0.00%) | 1 (2.7%) | |
Losartan | 1 (3.0%) | 1 (2.7%) | |
Valsartan | 0 (0.00%) | 1 (2.7%) | |
Aspirin | 0 (0.00%) | 1 (2.7%) | |
Atorvastatin | 3 (9.1%) | 0 (0.00%) | |
Levothyroxine | 0 (0.00%) | 2 (5.4%) | |
Amlodipine | 0 (0.00%) | 1 (2.7%) | |
Metformin + Losartan + Atorvastatin + Pantoprazole + Propranolol | 2 (6.1%) | 1 (2.7%) | |
Losartan + Furosemide + Atorvastatin + Aspirin | 1 (3.0%) | 0 (0.00%) | |
Metformin + Rosuvastatin + Aspirin | 1 (3.0%) | 0 (0.00%) | 0.367 |
Losartan + Aspirin | 1 (3.0%) | 1 (2.7%) | |
Losartan + Atorvastatin + Aspirin | 1 (3.0%) | 0 (0.00%) | |
Atorvastatin + Aspirin | 0 (0.00%) | 1 (2.7%) | |
Metformin + Glibenclamide | 1 (3.0%) | 0 (0.00%) | |
Losartan + Atorvastatin | 0 (0.00%) | 2 (5.4%) | |
Metformin + Atorvastatin + Levothyroxine | 0 (0.00%) | 1 (2.7%) | |